Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Organizations in 29 countries are eligible for emergency funds, support for longer term measures to counter treatment barriers In the weeks after Nigeria passed its 2014 […]
While more than half a million fell ill with drug-resistant tuberculosis requiring second-line treatments last year, just one in five received it Improved data collection shows […]
From a human-scented mosquito trap to rapid diagnostics, USAID funds research and development against Zika
Agency picks 21 of 900 ideas from around the world A research center in Tanzania will develop inexpensive sandals treated to ward off mosquito bites. Investigators […]
In the chaos of delayed responses to the Ebola crisis in West Africa, patterns emerged in data from five treatment centers across two of the three […]